Patients receiving immunosuppressive therapy are being put at risk of severe hepatitis flares and liver failure because they are not being tested for hepatitis B infection prior to starting therapy, a South Australian study shows. Although screening is recommended in guidelines to avoid reactivation of hepatitis B infection by immunomodulator drugs, only about half of patients taking ...
Oncologists need education on rituximab screening tests, liver specialists say
By Michael Woodhead
25 Jan 2018